The incidence of radiation toxicity is on the rise with the increase in treatment and diagnosis of various diseases using radiation therapy and nuclear medicine, thus driving the overall market’s growth. Radiation therapy is commonly used in cancer treatment to treat tumors and cancerous cells. The growing prevalence of cancer thus increases the rate of radiation therapy, indicating a growing risk of radiation toxicity. The American Cancer Society projected 1,735,350 new cancer cases to occur in the US in 2018 and further estimated 609,640 deaths to occur in a similar year. Based on various research studies, around 60% of patients undergo radiation therapy, of which 5–10% experience radiation toxicity. However, the high cost of radiation therapy would lead to fewer patients opting for it, particularly in low- and middle-income regions. This factor could reduce the rate of radiation toxicities, thus restraining market growth.
Radiation toxicity treatment options include bone marrow transplant, blood and platelet transfusion (used to treat anemia), and antibiotics (prescribed to reduce the risk of various infections). Aeolus Pharmaceuticals is currently developing (Phase I) a molecule named AEOL-10150 for the treatment of acute radiation syndrome.
Radiation toxicity can occur as a result of either intentional or unintentional radiation exposure, such as nuclear power plant accidents. Providing first aid to radiation victims may also increase the risk of exposure to radiation for the rescue personnel. The rising number of respective patients has attracted many pharmaceutical industries to invest in this market and carry out various research activities in the development of suitable therapies.
North America dominates the global radiation toxicity treatment market, which is followed by Europe. The dominance is attributed to the growing awareness of available treatment options. Asia Pacific is also a potential market owing to its developing healthcare infrastructure, rising awareness about healthcare, and growing cancer prevalence.
The global radiation toxicity (radiation sickness, acute radiation syndrome) treatment market is segmented as follows:
- Blood products
- Colony-stimulating factors
- Bone marrow transplant
- stem cell transplant
- Blood/platelet transfusions
- (Phase II) Temporary
- AEOL-10150 (Phase I)
- Rest of Europe
- Rest of Asia Pacific
- rest of Latin America
Middle East and Africa
- Rest of the Middle East and Africa
The key industrial players enjoying supremacy in this market are Aeolus Pharmaceuticals, Cantex Pharmaceuticals, Inc., Cleveland BioLabs, Inc., Gamida Cell Ltd., Nanotherapeutics, Inc., NeoStem, Inc., Onconova Therapeutics, Inc., Osiris Therapeutics, Inc., and Tonix Pharmaceuticals Holding Corp.
This report offers the following:
- An overview of the global radiation toxicity (radiation sickness, acute radiation syndrome) treatment market
- Market outlook and in-depth analysis for the period from 2016 to 2026, with 2016 as the historical year and 2017 as the base year
- Annual growth rates for the period from 2018 to 2026 pertaining to the entire market and each segment have also been included in this report.
- Qualitative information with respect to market drivers, opportunities, and restraints
- A complete understanding of the competitive landscape and profiles of key market players